| Buprenorphine is an opiod medication used in the | | | | for opioid dependence can be divided into 6 phases: |
| treatment of opioid addiction. It is usually dispensed | | | | Pretreatment Screening: The goal in this phase is to |
| by a physician as a take home treatment. Heroin and | | | | determine whether office based treatment is best |
| other opiate addictions can be safely treated and by | | | | course of action for a particular patient. It consists of |
| the process of gaining American FDA approval it has | | | | a brief interview conducted over phone or in person. |
| crossed one major hurdle. | | | | Intake: patients accepted for treatment in the |
| While Buprenorphine is the generic name for a | | | | pretreatment screening are then scheduled for intake. |
| chemical compound, short form for Buprenorphine | | | | To establish the patient's medical record showing |
| Hydrochloride and is a semi-synthetic opioid. | | | | suitability for office based treatment is the main |
| Suboxone and Subutex are brand names of | | | | objective of the intake. |
| Buprenorphine-based medications. | | | | Induction: The chief goal is to safely suppress opioid |
| Suboxone contains 4 parts Buprenorphine and 1 part | | | | withdrawal as rapidly as possible with adequate doses |
| naloxone. Only active ingredient in Subutex is | | | | of SUBOXONE. The patient should be warned of |
| Buprenorphine. Most physicians prefer Suboxone | | | | possible moderate opioid withdrawal symptoms. This |
| because it is less likely to be misused due to | | | | stage usually lasts anywhere from 2-5 days and |
| presence of the naloxone. Even though Suboxone | | | | should begin immediately following intake. |
| was invented for the US market, it is available in | | | | Stabilization: During this stage the patient's |
| other countries as well. | | | | SUBOXONE dose is "fine-tuned." The objective is |
| Buprenorphine as a Cure | | | | being to find the minimum dose necessary to hold |
| For treating opiate addiction Buprenophine as an | | | | the patient in treatment and suppress opioid |
| analgesic may act as fourth medication other being | | | | withdrawal effects, and use. This is done with |
| methadone, naltrexone, and LAAM | | | | progressive dose adjustments. |
| (l-alpha-acetyl-methadol). Buprenorphine's unique | | | | Maintenance: |
| effects and pharmacology make it an attractive and | | | | Chief goals are: |
| clinically helpful treatment option. For example, | | | | Prevent opioid withdrawal symptoms |
| buprenorphine produces less euphoria than morphine | | | | Suppress opioid cravings |
| and heroin. Significant lower degree of sedation and | | | | Self-administered opioids are attenuated for use |
| respiratory depression is caused by buprenorphine | | | | Medically Supervised Withdrawal: Only when the |
| than other opiates; heroin overdoses gets dangerous | | | | patient and physician agree that it is beneficial, it is |
| when breathing gets slowed down. Even high doses | | | | done to them. The patient's SUBOXONE dose should |
| of buprenorphine--as much as 100 times the dose at | | | | be slowly tapered at a rate that both physician and |
| which it produces analgesia--do not produce | | | | patient consider acceptable. |
| dangerous respiratory effects. "Respiratory | | | | Patients should be prepared for the possibility of mild, |
| depression caused by buprenorphine is not of clinical | | | | transitory withdrawal symptoms, which may include |
| concern," says Segal, "which makes it an extremely | | | | reduced energy, reduced appetite, irritability, or |
| attractive treatment alternative." | | | | insomnia. |
| Buprenorphine being an agonist which are chemicals | | | | When applying SUBOXONE treatment, therapy and |
| that bind to and stimulate opiate receptors has limited | | | | psychosocial counseling should be continued and |
| side effects. | | | | regularly monitored. Person's recovery and well being |
| SUBOXONE Treatment | | | | are dependent on these steps. |
| The use of Suboxone as an office based treatment | | | | |